GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Turk Ilac ve Serum Sanayi (IST:TRILC) » Definitions » Capex-to-Revenue

Turk Ilac ve Serumnayi (IST:TRILC) Capex-to-Revenue : 0.01 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Turk Ilac ve Serumnayi Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Turk Ilac ve Serumnayi's Capital Expenditure for the three months ended in Sep. 2023 was ₺-4.12 Mil. Its Revenue for the three months ended in Sep. 2023 was ₺435.88 Mil.

Hence, Turk Ilac ve Serumnayi's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.01.


Turk Ilac ve Serumnayi Capex-to-Revenue Historical Data

The historical data trend for Turk Ilac ve Serumnayi's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turk Ilac ve Serumnayi Capex-to-Revenue Chart

Turk Ilac ve Serumnayi Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial - - 0.09 0.03 0.05

Turk Ilac ve Serumnayi Quarterly Data
Dec17 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.05 0.03 0.13 0.01

Competitive Comparison of Turk Ilac ve Serumnayi's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turk Ilac ve Serumnayi's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Turk Ilac ve Serumnayi's Capex-to-Revenue falls into.



Turk Ilac ve Serumnayi Capex-to-Revenue Calculation

Turk Ilac ve Serumnayi's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-38.421) / 833.438
=0.05

Turk Ilac ve Serumnayi's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-4.123) / 435.882
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turk Ilac ve Serumnayi  (IST:TRILC) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Turk Ilac ve Serumnayi Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Turk Ilac ve Serumnayi's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Turk Ilac ve Serumnayi (IST:TRILC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Bügduz Mah. Enver Pasa Cad., No: 8 Akyurt, Ankara, TUR, TR 06750
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.

Turk Ilac ve Serumnayi (IST:TRILC) Headlines

No Headlines